---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-047941"
form_type: "8-K"
ticker: "CADL"
cik: "0001841387"
company_name: "Candel Therapeutics, Inc."
filed_at: "2024-04-25T23:59:59+00:00"
generated_at: "2026-06-03T08:12:45.643903+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Candel to present CAN-3110 glioma data and CAN-2409 NSCLC topline OS at ASCO 2024

## Summary
- Two abstracts accepted for ASCO 2024: CAN-3110 phase 1 (recurrent high-grade glioma, cohort C) and CAN-2409 phase 2 (NSCLC with inadequate ICI response).
- CAN-3110 data: multiple injections (up to six) feasible and well tolerated in cohort C.
- CAN-2409 presentation will show topline overall survival data with valacyclovir + continued ICI.
- Presentations on June 1 (CAN-3110) and June 3 (CAN-2409) at ASCO in Chicago.
- Full abstracts released by ASCO on May 23, 2024.

## SEC filing metadata
- accession: 0000950170-24-047941
- form_type: 8-K
- ticker: CADL
- cik: 0001841387
- company_name: Candel Therapeutics, Inc.
- filed_at: 2024-04-25T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1841387/000095017024047941/0000950170-24-047941-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1841387/000095017024047941/cadl-20240425.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-047941
- JSON: https://secwatch.observer/filing/0000950170-24-047941.json
- Plain text: https://secwatch.observer/filing/0000950170-24-047941.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.